Disease stage-specific atrophy markers in Alzheimer's disease
Baumeister, Hannah LU ; Gellersen, Helena M ; Polk, Sarah E ; Lattmann, René ; Wuestefeld, Anika LU
; Wisse, Laura E M
LU
; Glenn, Trevor
; Yakupov, Renat
; Stark, Melina
and Kleineidam, Luca
, et al.
(2025)
In Alzheimer's & dementia : the journal of the Alzheimer's Association
21(7).
- Abstract
INTRODUCTION: Structural magnetic resonance imaging (MRI) often lacks diagnostic, prognostic, and monitoring value in Alzheimer's disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal atrophy markers for different intended uses.
METHODS: We included 363 older adults; cognitively unimpaired individuals who were negative or positive for amyloid beta (Aβ) and Aβ-positive patients with subjective cognitive decline, mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to 3 years.
RESULTS: Accelerated atrophy of medial temporal lobe subregions was evident already during preclinical AD. Symptomatic... (More)
INTRODUCTION: Structural magnetic resonance imaging (MRI) often lacks diagnostic, prognostic, and monitoring value in Alzheimer's disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal atrophy markers for different intended uses.
METHODS: We included 363 older adults; cognitively unimpaired individuals who were negative or positive for amyloid beta (Aβ) and Aβ-positive patients with subjective cognitive decline, mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to 3 years.
RESULTS: Accelerated atrophy of medial temporal lobe subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Atrophy-cognition relationships varied by intended use and disease stage.
DISCUSSION: With the appropriate marker, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, atrophy markers should be tailored to the targeted disease stage and intended use.
HIGHLIGHTS: Subregional atrophy markers detect ongoing atrophy in preclinical Alzheimer's disease (AD). Subjective cognitive decline in preclinical AD links to manifest atrophy. Optimal atrophy markers differ by the disease stage and intended use.
(Less)
- author
- Baumeister, Hannah
LU
; Gellersen, Helena M
; Polk, Sarah E
; Lattmann, René
; Wuestefeld, Anika
LU
; Wisse, Laura E M
LU
; Glenn, Trevor
; Yakupov, Renat
; Stark, Melina
and Kleineidam, Luca
, et al. (More)
- Baumeister, Hannah
LU
; Gellersen, Helena M
; Polk, Sarah E
; Lattmann, René
; Wuestefeld, Anika
LU
; Wisse, Laura E M
LU
; Glenn, Trevor
; Yakupov, Renat
; Stark, Melina
; Kleineidam, Luca
; Roeske, Sandra
; Morgado, Barbara Marcos
; Esselmann, Hermann
; Brosseron, Frederic
; Ramirez, Alfredo
; Lüsebrink, Falk
; Synofzik, Matthis
; Schott, Björn H
; Schmid, Matthias C
; Hetzer, Stefan
; Dechent, Peter
; Scheffler, Klaus
; Ewers, Michael
; Hellmann-Regen, Julian
; Ersözlü, Ersin
; Spruth, Eike
; Gemenetzi, Maria
; Fliessbach, Klaus
; Bartels, Claudia
; Rostamzadeh, Ayda
; Glanz, Wenzel
; Incesoy, Enise I
; Janowitz, Daniel
; Rauchmann, Boris-Stephan
; Kilimann, Ingo
; Sodenkamp, Sebastian
; Coenjaerts, Marie
; Spottke, Annika
; Peters, Oliver
; Priller, Josef
; Schneider, Anja
; Wiltfang, Jens
; Buerger, Katharina
; Perneczky, Robert
; Teipel, Stefan
; Laske, Christoph
; Wagner, Michael
; Ziegler, Gabriel
; Jessen, Frank
; Düzel, Emrah
and Berron, David
LU
(Less)
- author collaboration
- organization
- publishing date
- 2025-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Alzheimer Disease/pathology, Atrophy/pathology, Magnetic Resonance Imaging, Male, Female, Aged, Cognitive Dysfunction/pathology, Neuropsychological Tests, Biomarkers, Amyloid beta-Peptides, Brain/pathology, Disease Progression, Aged, 80 and over, Hippocampus/pathology
- in
- Alzheimer's & dementia : the journal of the Alzheimer's Association
- volume
- 21
- issue
- 7
- article number
- e70482
- publisher
- Wiley
- external identifiers
-
- pmid:40691867
- ISSN
- 1552-5279
- DOI
- 10.1002/alz.70482
- language
- English
- LU publication?
- yes
- additional info
- © 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
- id
- fe43d2b6-eb7a-4896-bc52-6c870f397292
- date added to LUP
- 2025-08-04 07:35:41
- date last changed
- 2025-08-04 13:14:39
@article{fe43d2b6-eb7a-4896-bc52-6c870f397292,
abstract = {{<p>INTRODUCTION: Structural magnetic resonance imaging (MRI) often lacks diagnostic, prognostic, and monitoring value in Alzheimer's disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal atrophy markers for different intended uses.</p><p>METHODS: We included 363 older adults; cognitively unimpaired individuals who were negative or positive for amyloid beta (Aβ) and Aβ-positive patients with subjective cognitive decline, mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to 3 years.</p><p>RESULTS: Accelerated atrophy of medial temporal lobe subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Atrophy-cognition relationships varied by intended use and disease stage.</p><p>DISCUSSION: With the appropriate marker, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, atrophy markers should be tailored to the targeted disease stage and intended use.</p><p>HIGHLIGHTS: Subregional atrophy markers detect ongoing atrophy in preclinical Alzheimer's disease (AD). Subjective cognitive decline in preclinical AD links to manifest atrophy. Optimal atrophy markers differ by the disease stage and intended use.</p>}},
author = {{Baumeister, Hannah and Gellersen, Helena M and Polk, Sarah E and Lattmann, René and Wuestefeld, Anika and Wisse, Laura E M and Glenn, Trevor and Yakupov, Renat and Stark, Melina and Kleineidam, Luca and Roeske, Sandra and Morgado, Barbara Marcos and Esselmann, Hermann and Brosseron, Frederic and Ramirez, Alfredo and Lüsebrink, Falk and Synofzik, Matthis and Schott, Björn H and Schmid, Matthias C and Hetzer, Stefan and Dechent, Peter and Scheffler, Klaus and Ewers, Michael and Hellmann-Regen, Julian and Ersözlü, Ersin and Spruth, Eike and Gemenetzi, Maria and Fliessbach, Klaus and Bartels, Claudia and Rostamzadeh, Ayda and Glanz, Wenzel and Incesoy, Enise I and Janowitz, Daniel and Rauchmann, Boris-Stephan and Kilimann, Ingo and Sodenkamp, Sebastian and Coenjaerts, Marie and Spottke, Annika and Peters, Oliver and Priller, Josef and Schneider, Anja and Wiltfang, Jens and Buerger, Katharina and Perneczky, Robert and Teipel, Stefan and Laske, Christoph and Wagner, Michael and Ziegler, Gabriel and Jessen, Frank and Düzel, Emrah and Berron, David}},
issn = {{1552-5279}},
keywords = {{Humans; Alzheimer Disease/pathology; Atrophy/pathology; Magnetic Resonance Imaging; Male; Female; Aged; Cognitive Dysfunction/pathology; Neuropsychological Tests; Biomarkers; Amyloid beta-Peptides; Brain/pathology; Disease Progression; Aged, 80 and over; Hippocampus/pathology}},
language = {{eng}},
number = {{7}},
publisher = {{Wiley}},
series = {{Alzheimer's & dementia : the journal of the Alzheimer's Association}},
title = {{Disease stage-specific atrophy markers in Alzheimer's disease}},
url = {{http://dx.doi.org/10.1002/alz.70482}},
doi = {{10.1002/alz.70482}},
volume = {{21}},
year = {{2025}},
}